North Bay Eye Associates, Inc. Research Department

11/03/2025

Please take a minute to read Dr. Bacharach’s latest article published by Doverpress, and comment if you spot El Jefe!

Expert Opinion to Optimize Clinical Outcomes of Bimatoprost Intracameral Implant Treatment

10/24/2025

👁️ Do you have Glaucoma or High Eye Pressure?

You may qualify to participate in a clinical research study at North Bay Eye Associates!

This study is designed for adults (18+) with primary open-angle glaucoma or ocular hypertension who are currently being treated with eye pressure–lowering medication.

🧠 Why participate?
• Receive study-related medication and exams at no cost
• Help advance glaucoma research
• You may be compensated for your time and travel

📅 Participation may last up to 15 months and include 14 visits.

📞 Interested?
Contact North Bay Eye Associates, Research at 707-769-2237 to learn more and find out if you qualify!

💡 Don’t miss this opportunity to make a difference in glaucoma research with PolyActiva.

10/10/2025

We invite you to join Dr. Bacharach at the Sunshine Eye & Retina Meeting.

10/07/2025

👁️ Help Advance Glaucoma Research!

Do you or someone you know have open-angle glaucoma or high eye pressure?

10/03/2025

Have you been diagnosed with glaucoma? You may be eligible to participate in and benefit from our innovative clinical trial—please take a moment to read more.

09/22/2025

NBEA did it again! We had such a wonderful time at this year’s annual team picnic. From the amazing variety of carnival games, and prizes to the amazing Hawaiian  dancers to the delicious food (we could go for those freshly made tacos every day!), it was a day to remember. A huge thank-you to everyone who helped plan and organize the event, you truly rock and did an outstanding job, as always!

09/04/2025

Congratulations to Dr. Bacharach on his upcoming speaking engagement at Hawaiian Eye and Retina 2026!

07/31/2025

Congratulations to LENZ Therapeutics, Inc. on their recent FDA approval of their aceclidine-based eye drop for the treatment of presbyopia! It was both an honor and a pleasure to be part of this incredible journey.

Now a special message from our Principle Investigator (PI) Dr. Bacharach: Congrats to everyone at NBEA who helped advance this new option for presbyopic patients to the US Market place.

Whether you were a doctor who participated in the trial or support staff who recommended a patient in to the trial- we are very grateful!

SAN DIEGO, CA – July 31, 2025 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced the US Food and Drug Administration (“FDA”) approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treat...

07/31/2025

https://rankings.newsweek.com/americas-leading-doctors-2025-glaucoma-surgery

Congratulations to Dr. Bacharach for being recognized on Newsweek’s 2025 list of America’s Leading Doctors in Glaucoma Surgery!

Navigating a serious health issue can be daunting, especially with so many specialists and treatment options to consider. To help patients find top-tier care, Newsweek and Statista are proud to present America’s Leading Doctors 2025, recognizing over 2,000 of the top doctors across the country.

07/28/2025

https://pubmed.ncbi.nlm.nih.gov/40147597/

The ocular pressure adjusting pump safely and effectively lowers both daytime and nocturnal IOP in patients with NTG.

07/28/2025

https://pubmed.ncbi.nlm.nih.gov/40043909/

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

07/28/2025

https://pmc.ncbi.nlm.nih.gov/articles/PMC11984482/

Ophthalmic medications administered via standardized eyedrop bottles have an average drop size of 40 µL, but absorption is limited to the conjunctival sac volume of 7–10 µL. The Nanodropper is a commercially available eyedrop bottle adapter capable ...